公开(公告)号：NZ579048A

公开(公告)日：2012-05-25

申请号：NZ57904808

申请日：2008-01-30

Applicant: PHARMACYCLICS INC

Inventor： BUGGY JOSEPH J ,  BALASUBRAMANIAN SRIRAM

IPC: A61K49/00 ,  C12Q1/68 ,  G01N33/574

Abstract: Disclosed are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor.

公开(公告)号：CA2683822A1

公开(公告)日：2008-10-23

申请号：CA2683822

申请日：2008-04-11

Applicant: PHARMACYCLICS INC

Inventor： BUGGY JOSEPH J ,  RAMOS JASON ,  SIRISAWAD MINT ,  BALASUBRAMANIAN SRIRAM

IPC: A61K38/18

Abstract: Described herein are methods for using calcium flux as a biomarker to sel ect and predict patients likely to respond to an apoptotic agent as therapy. Further described herein is a method of using calcium flux as a clinical bi omarker to determine whether a tumor is sensitive to an HDAC inhibitor.

公开(公告)号：CA2677000A1

公开(公告)日：2008-08-07

申请号：CA2677000

申请日：2008-01-30

Applicant: PHARMACYCLICS INC

Inventor： BUGGY JOSEPH J ,  BALASUBRAMANIAN SRIRAM

IPC: A61K49/00 ,  C12Q1/68 ,  G01N33/574

Abstract: [00153] Described herein are methods and compositions for determining whe ther a particular cancer is resistant to or susceptible to a histone deacety lase inhibitor or to histone deacetylase inhibitors. The methods include ana lysis of the expression levels of at least four biomarker genes associated w ith response to a histone deacetylase inhibitor. Also described herein are m ethods and compositions for increasing the likelihood of a therapeutically e ffective treatment in a patient, comprising an analysis of the expression le vels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nuc leic acids derived from a cancer sensitive to or resistant to a histone deac etylase inhibitor. Further described are kits and indications that are used in conjunction with the aforementioned methods and compositions.

公开(公告)号：EP2814493A4

公开(公告)日：2015-07-22

申请号：EP13748860

申请日：2013-02-15

Applicant: PHARMACYCLICS INC

Inventor： BALASUBRAMANIAN SRIRAM ,  MODY TARAK D

IPC: A61K31/506 ,  A61K31/343 ,  A61P35/00

CPC classification number: A61K31/343 ,  A61K31/506 ,  A61K45/06 ,  A61N5/10 ,  A61K2300/00

公开(公告)号：EP2144622A4

公开(公告)日：2010-06-09

申请号：EP08745659

申请日：2008-04-11

Applicant: PHARMACYCLICS INC

Inventor： BALASUBRAMANIAN SRIRAM ,  BUGGY JOSEPH J ,  RAMOS JASON ,  SIRISAWAD MINT

IPC: G01N33/84 ,  G01N33/574

CPC classification number: G01N33/57438 ,  G01N33/6872 ,  G01N33/84 ,  G01N2800/52

公开(公告)号：AU2011376953B2

公开(公告)日：2017-08-24

申请号：AU2011376953

申请日：2011-09-13

Applicant: LES LABORATOIRES SERVIER SAS ,  PHARMACYCLICS INC

Inventor： LOURY DAVID J ,  BUGGY JOSEPH J ,  MODY TARAK D ,  VERNER ERIK J ,  PURRO NORBERT ,  BALASUBRAMANIAN SRIRAM ,  KLOOS IOANA ,  DEPIL STEPHANE

IPC: A61K31/343 ,  A61K31/16 ,  A61K31/166 ,  A61P35/00

Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

公开(公告)号：SG10201607620YA

公开(公告)日：2016-11-29

申请号：SG10201607620Y

申请日：2011-09-13

Applicant: PHARMACYCLICS INC ,  SERVIER SAS LAB

Inventor： LOURY DAVID J ,  BUGGY JOSEPH J ,  MODY TARAK D ,  VERNER ERIK J ,  PURRO NORBERT ,  BALASUBRAMANIAN SRIRAM ,  KLOOS IOANA ,  DEPIL STÉPHANE

公开(公告)号：HK1201150A1

公开(公告)日：2015-08-28

申请号：HK14112851

申请日：2014-12-23

Applicant: PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  ROBERT RENATA ,  JACQUET-BESCOND ANNE ,  DEPIL STPHANE ,  CHENEL MARYLORE ,  FOULIARD SYLVAIN ,  BALASUBRAMANIAN SRIRAM

IPC: A61K20060101 ,  A61P20060101

Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.

公开(公告)号：MX2014009892A

公开(公告)日：2015-02-12

申请号：MX2014009892

申请日：2013-02-15

Applicant: PHARMACYCLICS INC

Inventor： MODY TARAK D ,  BALASUBRAMANIAN SRIRAM

IPC: A61K31/506 ,  A61K31/517 ,  A61P35/00

Abstract: Se describen pautas de dosificación, procedimientos de tratamiento, formulaciones de liberación controlada y terapias de combinación que incluyen un inhibidor de HDAC, o una sal farmacéuticamente aceptable del mismo, y pazopanib (o una sal del mismo; por ejemplo, HC1 de pazopanib).

公开(公告)号：CA2847011A1

公开(公告)日：2013-03-14

申请号：CA2847011

申请日：2012-09-07

Applicant: SERVIER LAB ,  PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  ROBERT RENATA ,  JACQUET-BESCOND ANNE ,  DEPIL STEPHANE ,  CHENEL MARYLORE ,  FOULIARD SYLVAIN ,  BALASUBRAMANIAN SRIRAM

IPC: A61K31/138 ,  A61K31/343 ,  A61K31/704 ,  A61K33/24 ,  A61P35/00

Abstract: NOUVEAU SCHEMA D'ADMINISTRATION DU W-HYDROXY-4-{2-[3-(W,W-DIMETHYLAMINOMETHYL)BENZOFU- RAN-2-YLCARBONYLAMINO]ETHOXY} BENZAMIDE /V-hydroxy-4-{2-[3-{/V,/V-diméthylaminométhyl)benzofu- ran-2-ylcarbonylamino]éthoxy} benzamide de formule (I) : ou un de ses sels d'addition à un acide ou à une base pharmaceutiquement acceptable, seul ou en association avec un traitement de chirurgie, de chimiothérapie, d'hormonothérapie ou avec la radiothérapie, pour le traitement du cancer, caractérisé en ce qu'il est administré pendant 4 jours consécutifs, cette période étant suivie de 3 jours consécutifs sans aucune administration du composé de formule (I), étant entendu que le traitement de chimiothérapie n'est pas le FOLFOX.